OR WAIT null SECS
Director of Berkeley Research Group explains changes to 340B moving forward.
In an interview with Pharmaceutical Commerce editor Nicholas Saraceno, Andrew Brownlee, director, Berkeley Research Group, offers insight on how the 340B landscape will continue to evolve as time goes on.
Brownlee: Quite a bit of where the 340B program stands today is subject to ongoing litigation. We'll be following that to see what develops from the legal landscape. In addition to that, we can anticipate that last year's Inflation Reduction Act (IRA) can also have some impact on the program as there are provisions that interact with 340B. It'll be important for stakeholders within 340B to understand the overlaps between it and the IRA. It is still a question of how some of those aspects will be operationalized.